tiprankstipranks
Advertisement
Advertisement

ABCL Stock Latest News

Largest borrow rate increases among liquid names
The FlyLargest borrow rate increases among liquid names
7d ago
ALM
IRE
AbCellera Biologics Bets Big on 2026 Trial Catalysts
PremiumCompany Announcements
AbCellera Biologics Bets Big on 2026 Trial Catalysts
15d ago
ABCL
Evan Seigerman Reiterates Buy on AbCellera, Citing Strong ABCL635 Phase 1 Data and Platform Strength; $7 Price Target Maintained
PremiumRatings
Evan Seigerman Reiterates Buy on AbCellera, Citing Strong ABCL635 Phase 1 Data and Platform Strength; $7 Price Target Maintained
15d ago
ABCL
AbCellera price target raised to $8 from $7 at Stifel
PremiumThe Fly
AbCellera price target raised to $8 from $7 at Stifel
15d ago
ABCL
AbCellera Biologics options imply 9.7% move in share price post-earnings
PremiumThe Fly
AbCellera Biologics options imply 9.7% move in share price post-earnings
16d ago
ABCL
AbCellera reports Q1 EPS (14c), consensus (20c)
PremiumThe FlyAbCellera reports Q1 EPS (14c), consensus (20c)
16d ago
ABCL
ABCL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ABCL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
18d ago
ABCL
AbCellera initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
AbCellera initiated with an Overweight at Cantor Fitzgerald
22d ago
ABCL
AbCellera: Strategic Pivot to an Internal Pipeline and Key ABCL635 Readouts Position Shares for Multibillion-Dollar Upside
PremiumRatings
AbCellera: Strategic Pivot to an Internal Pipeline and Key ABCL635 Readouts Position Shares for Multibillion-Dollar Upside
1M ago
ABCL
AbCellera target is profile more attractive than Vistagen, says JonesResearch
PremiumThe Fly
AbCellera target is profile more attractive than Vistagen, says JonesResearch
1M ago
ABCL
VTGN
AbCellera: De-Risked Antibody Platform With High-Value Menopause Lead and Underappreciated Pipeline Optionality Supporting Buy Rating
PremiumRatings
AbCellera: De-Risked Antibody Platform With High-Value Menopause Lead and Underappreciated Pipeline Optionality Supporting Buy Rating
2M ago
ABCL
AbCellera initiated with a Buy at JonesResearch
PremiumThe Fly
AbCellera initiated with a Buy at JonesResearch
2M ago
ABCL
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks
PremiumCompany AnnouncementsAbcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks
3M ago
ABCL
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts
Premium
Company Announcements
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts
3M ago
ABCL
AbCellera reports FY25 EPS (49c) vs. (55c) last year
Premium
The Fly
AbCellera reports FY25 EPS (49c) vs. (55c) last year
3M ago
ABCL
Is ABCL a Buy, Before Earnings?
PremiumPre-Earnings
Is ABCL a Buy, Before Earnings?
3M ago
ABCL
AbCellera doses first patients in Phase 2 portion of ABCL635 trial
PremiumThe Fly
AbCellera doses first patients in Phase 2 portion of ABCL635 trial
5M ago
ABCL
Viking Therapeutics names Neil Aubuchon as Chief Commercial Officer
PremiumThe Fly
Viking Therapeutics names Neil Aubuchon as Chief Commercial Officer
5M ago
ABCL
VKTX
AbCellera Secures Global Settlement and Patent License Deal
PremiumCompany Announcements
AbCellera Secures Global Settlement and Patent License Deal
5M ago
8K
ABCL
AbCellera to receive $36M upfront in patent litigation settlement with Bruker
PremiumThe FlyAbCellera to receive $36M upfront in patent litigation settlement with Bruker
5M ago
ABCL
BRKR
Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics
Premium
Ratings
Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics
6M ago
ABCL
AbCellera Appoints Dr. Stephen Quake to Board
Premium
Company Announcements
AbCellera Appoints Dr. Stephen Quake to Board
7M ago
8K
ABCL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >